This article corrects:

  1. Rilonacept and canakinumab Volume 71, Issue 5, 639–641, Article first published online: 11 April 2011

Dubois EA, Rissmann R & Cohen AF. Rilonacept and canakinumab. Br J Clin Pharmacol 2011; 71: 639–41.

In [1] there was an error in the drawing of rilonacept molecule (Figure 2). This protein was depicted as heterodimeric antibody but it should show a homodimer consisting of the in-line, fused extracellular domains of IL-1RAcP and the mature extracellular domains of IL-1R1 and the Fc portion of human IgG1 [2].

The first sentence of the fifth paragraph should have read ‘Rilonacept is a homodimer and consists of the extracellular domains of the IL-1-RAcP and the IL-1-R1 fused to the Fc portion of human IgG1’.

The second sentence of the legend of figure 2 should have read ‘Inset: The antibody rilonacept is composed of a human IgG1 FC domain (white) with the 2 arms specific for IL-1 binding: the extracellular domains of the IL-1 receptor 1 (IL-1-R1 in blue) and of the IL-1 receptor accessory protein (IL-1-RAcP in green) fused in-line on each arm to form a homodimeric antibody.’

We regret the error and apologize for it.


  • image(2)

[ ]